![Konstantinos STROUMPOULIS | MD, PhD | CMP - Centre Hospitalier du Nord Deux-Sèvres, Bressuire | Anesthesiology Department Konstantinos STROUMPOULIS | MD, PhD | CMP - Centre Hospitalier du Nord Deux-Sèvres, Bressuire | Anesthesiology Department](https://i1.rgstatic.net/ii/profile.image/272289950334979-1441930391111_Q512/Konstantinos-Stroumpoulis.jpg)
Konstantinos STROUMPOULIS | MD, PhD | CMP - Centre Hospitalier du Nord Deux-Sèvres, Bressuire | Anesthesiology Department
Yolanda Douglas - Vice President, Senior Trust Administrator at BMO Harris Bank - BMO Harris Bank | LinkedIn
![PDF) A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer PDF) A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer](https://i1.rgstatic.net/publication/318300692_A_randomised_open-label_phase_2_study_of_the_IDO1_inhibitor_epacadostat_INCB024360_versus_tamoxifen_as_therapy_for_biochemically_recurrent_CA-125_relapse-only_epithelial_ovarian_cancer_primary_periton/links/5b4518860f7e9b1c7223436e/largepreview.png)
PDF) A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
![Konstantinos STROUMPOULIS | MD, PhD | CMP - Centre Hospitalier du Nord Deux-Sèvres, Bressuire | Anesthesiology Department Konstantinos STROUMPOULIS | MD, PhD | CMP - Centre Hospitalier du Nord Deux-Sèvres, Bressuire | Anesthesiology Department](https://i1.rgstatic.net/ii/profile.image/1088269005656066-1636474958367_Q128/Ioannis-Pantazopoulos-2.jpg)
Konstantinos STROUMPOULIS | MD, PhD | CMP - Centre Hospitalier du Nord Deux-Sèvres, Bressuire | Anesthesiology Department
![Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty in: European Journal of Endocrinology Volume 165 Issue 2 (2011) Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty in: European Journal of Endocrinology Volume 165 Issue 2 (2011)](https://eje.bioscientifica.com/view/journals/eje/165/2/images/large/233fig2.jpeg)
Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty in: European Journal of Endocrinology Volume 165 Issue 2 (2011)
![Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects | Request PDF Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects | Request PDF](https://c5.rgstatic.net/m/4671872220764/images/template/default/profile/profile_default_m.jpg)
Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects | Request PDF
![Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer | PNAS Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer | PNAS](https://www.pnas.org/content/94/15/8099/F1.large.jpg)
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer | PNAS
![Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients | PNAS Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients | PNAS](https://www.pnas.org/content/110/52/21083/F1.large.jpg)